immatics biotechnologies GmbH: history, ownership, mission, how it works & makes money

A Brief History of immatics biotechnologies GmbH

Founded in 2000, immatics biotechnologies GmbH is a biopharmaceutical company based in Tübingen, Germany, specializing in the development of cancer immunotherapies. The company focuses on harnessing the power of the immune system to target and eliminate tumor cells. Over the years, immatics has made significant strides in cancer treatment, particularly through its innovative peptide-based vaccines.

In 2008, immatics initiated a clinical trial for its lead product candidate, IMA901, a therapeutic cancer vaccine targeting multiple tumor-associated antigens. The Phase 2 trial results reported improved overall survival rates in patients with advanced renal cell carcinoma, leading to heightened interest from the oncology community.

By 2017, immatics established a strategic partnership with pharmaceutical giant Merck KGaA, Darmstadt, Germany, to develop IMVax, which combines the company’s peptide-based technology with Merck's immune-oncology strategies. This collaboration expanded immatics’ capabilities and strengthened its position in the competitive landscape of immunotherapy.

In 2020, immatics went public through a merger with a special purpose acquisition company (SPAC), raising approximately €135 million. The public listing allowed immatics to enhance its pipeline and fund the development of its lead therapies.

As of 2023, immatics has advanced several products into late-stage clinical trials. The company’s lead candidate, IMA201, is currently in Phase 2 trials targeting both head and neck and bladder cancers. Preliminary results have indicated promising efficacy, with a response rate of approximately 35% in treated patients.

In the fiscal year ending 2022, immatics reported a revenue of €14.2 million, primarily driven by collaborations and grant funding. The company’s focus on advancing its pipeline is evident as it allocates a substantial portion of its resources towards clinical development, with €50.1 million spent on R&D in the same period.

The company's market capitalization as of October 2023 stands at approximately €800 million, reflecting investor confidence in its product pipeline and strategic partnerships. Recent stock performance indicates a growth of 25% year-to-date, highlighting a positive market reaction to ongoing clinical trial successes.

Looking ahead, immatics aims to leverage its proprietary technology platform to not only expand its vaccine offerings but also explore other therapeutic avenues within immuno-oncology. With several additional candidates in preclinical stages, the company's future growth trajectory appears robust as it continues to push the boundaries of cancer treatment.

A Who Owns immatics biotechnologies GmbH

Immatics Biotechnologies GmbH is a biotechnology company focusing on the discovery and development of T cell-based immunotherapies for cancer treatment. As of 2023, the ownership structure of Immatics is comprised of various stakeholders, including institutional investors, company executives, and strategic partners.

As of the latest data, a significant part of Immatics is owned by institutional investors. The largest shareholders include:

The company went public through a merger with a special purpose acquisition company (SPAC) in 2021 which has significantly impacted its shareholder composition. Post-merger, the enterprise value was reported at approximately $500 million. Immatics raised approximately $180 million in gross proceeds during this transaction.

Additionally, Immatics has strategic partnerships that influence its operational funding and research capabilities. For example, its collaboration with Roche is focused on advancing immunotherapy treatments that leverage Immatics' proprietary technology platforms.

Financial performance metrics also paint a vivid picture of Immatics' positioning in the biotechnology market. In its most recent earnings report for Q2 2023, Immatics reported total revenues of $10 million, attributed mainly to research grants and milestone payments from collaborative agreements. The net loss for the quarter was reported at $15 million, highlighting the investment nature of biotechnology companies in their developmental phases.

The cash and cash equivalents stood at approximately $50 million as of June 2023, providing the company with a runway for ongoing clinical trials and operational expenses for the next 18-24 months. With several clinical trials in various phases, this financial cushion is critical for Immatics' continued growth.

immatics biotechnologies GmbH Mission Statement

immatics biotechnologies GmbH focuses on developing innovative cancer immunotherapies. The company aims to harness the power of the immune system to fight tumors, with a strong commitment to improving patient outcomes through advanced biopharmaceutical research and development.

The mission statement of immatics emphasizes their dedication to identifying and developing novel therapeutic options that specifically target cancer cells while sparing normal tissues, thereby minimizing side effects. This objective is reflected in their pipeline of programs, leveraging proprietary T-cell receptor (TCR) technology.

As of the latest financial reports, immatics boasts a robust financial standing with total revenue reaching approximately €15 million in 2022, showing a steady increase from previous years. Their commitment to R&D is reflected in their investments, amounting to €16 million in the same year.

The strategic focus on advancing their clinical pipeline continues to yield promising results. Currently, immatics has several programs in clinical trials, including IMA201 and IMA202, which demonstrate significant potential in targeting various cancers. The company’s mission underlines the importance of these developments, placing them at the forefront of immunotherapy innovation.

In addition to their clinical programs, immatics is actively pursuing partnerships to enhance their research capabilities and expand their market reach. Collaborations have been instrumental in driving innovation, with strategic alliances contributing over €10 million in funding since 2020.

Overall, immatics biotechnologies GmbH’s mission statement encapsulates their forward-thinking approach, dedication to patient care, and commitment to advancing cancer immunotherapy, positioning them as a key player in the biotech industry.

How immatics biotechnologies GmbH Works

Immatics biotechnologies GmbH specializes in the development of innovative cancer immunotherapy solutions. The company employs a proprietary technology platform known as the XPRESIDENT® platform, which is designed to identify and validate tumor-specific target antigens for immune therapies. This platform is critical as it enables the discovery of novel tumor-associated peptides which are then used to create therapeutic vaccines and T cell therapies.

As of the latest data, the company has multiple product candidates in various stages of clinical development. One of the lead candidates, IMC-c963, targets the tumor-associated antigen PRAME and is currently in a Phase I/II clinical trial.

In their financial report for the fiscal year ending December 31, 2022, immatics reported revenue of €17.5 million, a notable increase from €12.3 million in 2021. The growth was primarily attributed to collaboration agreements and milestone payments from their partnerships.

The company's operational expenses for the same period amounted to €27.8 million, reflecting an increase as they intensified their R&D efforts and expanded clinical trials.

Immatics operates primarily by entering into strategic partnerships with larger pharmaceutical companies. Recently, they announced a collaboration with Bristol Myers Squibb to develop T cell therapies. This partnership is expected to enhance their R&D capabilities while leveraging Bristol Myers Squibb's extensive resources in oncology.

The company has also engaged in public offerings to fuel their pipeline. In July 2021, immatics completed an initial public offering (IPO) on the NASDAQ stock exchange, raising approximately $109 million in gross proceeds, which significantly bolstered their capital for ongoing research.

As of the most recent quarter ending September 30, 2023, immatics' share price was approximately €12.25, with a market capitalization of about €350 million. This reflects a volatile trading environment, underscoring the risks and opportunities inherent in the biotech sector.

Furthermore, immatics maintains robust intellectual property, holding over 300 patents globally, which provides a competitive advantage and secures their innovative therapies against potential market entrants.

The company's pipeline also features several other candidates, including IMC-001 for the treatment of gastric cancer and IMC-002 targeting melanoma, both currently advancing through clinical phases.

In terms of clinical advancements, immatics' products are positioned to benefit from the growing global immuno-oncology market, which is projected to reach $143.5 billion by 2025, highlighting the potential for impactful therapeutic solutions.

How immatics biotechnologies GmbH Makes Money

Immatics Biotechnologies GmbH is a privately-held biotechnology company specializing in the development of cancer immunotherapy products. The company's primary revenue streams include collaboration agreements, service agreements, and licensing of proprietary technologies.

Revenue Streams

The primary sources of income for Immatics include:

• Partnership and collaboration agreements with pharmaceutical companies.
• Revenue from clinical trial services.
• Licensing fees for proprietary technologies.
• Grants and funding from governmental and non-governmental organizations.

Partnership and Collaboration Agreements

In 2020, Immatics entered into a partnership with Amgen to develop advanced T-cell therapies, which included an upfront payment of approximately $25 million and potential future milestone payments that could total more than $1 billion.

In addition, collaborations with companies like Roche have provided access to both financial resources and expertise, significantly bolstering their R&D capabilities.

Service Agreements

Immatics offers contract research services, providing insights and data to pharmaceutical companies. In their last reported financial year, service agreements contributed revenue of approximately $10 million.

Licensing Fees

The licensing of their proprietary technologies brings in a steady revenue stream. In 2021, Immatics reported licensing income of around $3 million from various partners leveraging their innovative technologies in cancer treatment.

Grants and Funding

As an innovative biotech firm, Immatics also receives governmental and private grants. In 2022, the company secured a grant worth $5 million from the European Union’s Horizon 2020 program to aid in advanced drug development initiatives.

Financial Performance Overview

According to the latest financial report for 2022, Immatics reported total revenues of approximately $40 million, marking an increase of 30% from the previous year. Below is a summary of their financial performance:

Moreover, the company has been successful in advancing several candidates in clinical trials, which could further enhance their financial outlook. As of the latest updates, Immatics holds a robust pipeline with several candidates in different phases of clinical development, including their lead product, IMC-G117, which is currently in Phase II trials for treating solid tumors.

This diversity in revenue generation, combined with their innovative product pipeline, positions Immatics to potentially capitalize on the growing demand for targeted immunotherapies in oncology, anticipating a significant increase in revenue in the coming years.